%0 Journal Article
%T Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
%J -
%D 2019
%R https://doi.org/10.1038/s41408-019-0204-x
%X The role of umbilical cord blood transplantation (CBT) in acute myeloid leukemia (AML) patients with active disease at allogeneic hematopoietic cell transplantation (allo-HCT) remains poorly investigated. In this study, we compared transplantation outcomes of 2963 patients with primary refractory or relapsed AML given CBT, 10/10 HLA-matched UD, or 9/10 HLA-matched UD allo-HCT from 2004 to 2015 at EBMT-affiliated centers. Neutrophil engraftment and complete remission rates in CBT, UD 10/10, and UD 9/10 recipients were 75 and 48%, 93 and 69%, and 93 and 70%, respectively. In multivariate Cox analyses, in comparison with CBT (n£¿=£¿285), UD 10/10 recipients (n£¿=£¿2001) had a lower incidence of relapse (HR£¿=£¿0.7, P£¿=£¿0.001), a lower incidence of non relapse mortality (HR£¿=£¿0.6, P£¿<£¿0.001), better GVHD-free and leukemia-free survival (GRFS, HR£¿=£¿0.8, P£¿<£¿0.001) and better survival (HR£¿=£¿0.6, P£¿<£¿0.001). Further, in comparison with CBT, 9/10 UD recipients (n£¿=£¿677) also had a lower incidence of relapse (HR£¿=£¿0.8, P£¿=£¿0.02), a lower incidence of nonrelapse mortality (HR£¿=£¿0.7, P£¿=£¿0.008), better GRFS (HR£¿=£¿0.8, P£¿=£¿0.01) and better survival (HR£¿=£¿0.7, P£¿<£¿0.001). In summary, these data suggest that in AML patients with active disease at transplantation, allo-HCT with UD results in better transplantation outcomes than CBT
%U https://www.nature.com/articles/s41408-019-0204-x